CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is a multicenter, open-label, nonrandomized, Phase 2 umbrella study of retifanlimab in participants who have advanced or metastatic endometrial...
Phase 2
Phoenix, Arizona, United States and 66 other locations
participants with recurrent or primary advanced (Stage III or IV) endometrial cancer....
Phase 3
Phoenix, Arizona, United States and 162 other locations
drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer...
Phase 1
Phoenix, Arizona, United States and 75 other locations
choice (doxorubicin or paclitaxel) for the treatment of advanced endometrial cancer. Participants will be randomly assigned to rece...
Phase 3
Phoenix, Arizona, United States and 168 other locations
Phase.Cohort A: Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IO-treated)Cohort B: Advanced or Metastatic Triple Negative Bre ...
Phase 1, Phase 2
Phoenix, Arizona, United States and 15 other locations
This is a global, open-label, multicenter Phase 1/2 study to evaluate the safety, tolerability, PK, and antitumor activity of PRO1107 in patients wit...
Phase 1, Phase 2
Scottsdale, Arizona, United States and 3 other locations
This study, ELU- FRα-1, is focused on adult subjects who have advanced, recurrent or refractory folate receptor alpha (FRα) overexpressing tumors con...
Phase 1, Phase 2
Phoenix, Arizona, United States and 17 other locations
This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profile...
Phase 1
Scottsdale, Arizona, United States and 18 other locations
to other places in the body, it is called advanced or metastatic cancer. Participants in this study must have head and neck squamous cell ca ...
Phase 2
Chandler, Arizona, United States and 26 other locations
in participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon's OncoSigna...
Phase 1, Phase 2
Phoenix, Arizona, United States and 67 other locations
Clinical trials
Research sites
Resources
Legal